In 2016 Ing. Pavol Čekan, PhD. founded MultiplexDX, a biotechnology start-up to significantly advance cancer diagnosis. In December 2019, this company was the first in Slovakia to receive the prestigious €2.5 million European Innovation Council (EIC) Accelerator grant. He has recently participated in the project for manufacturing a PCR test for the detection of SARS-CoV-2 virus. He is a member of the Scientific Advisory Board of the Ministry of Health of the Slovak Republic and has received several prestigious awards highlighting his business and scientific achievements. He studied biochemistry in Iceland and worked at the Rockefeller University in New York in the laboratory of the well-known Professor Thomas Tuschl and at the prestigious National Cancer Institute in Maryland, USA.